Development of sunitinib in the treatment of imatinib-resistant gastrointestinal stromal tumors / 国际外科学杂志
International Journal of Surgery
;
(12): 132-135, 2011.
Artículo
en Chino
| WPRIM
| ID: wpr-400390
ABSTRACT
Sunitinib malate (SU11248 ,Sutent) is an orally available small-molecule multitargeted tyrosine kinase inhibitor that has potent anti-angiogenic and antitumour activities.In 2006 sunitinib was approved by FDA for imatinib intolerant gastrointestinal stromal tumors (GIST) patients or imatinib resistant GIST patients.This article review the molecular-based mechanism,the mechanism of resistance,the biomarker,the clinical trials and the adverse effects of sunitinib in the treatment of imatinib-resistant GIST.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
International Journal of Surgery
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS